193 related articles for article (PubMed ID: 37483630)
1. Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China.
Yan Y; Lv R; Wang T; Yu Y; Huang Y; Xiong W; Li Y; Sui W; Wang Q; Huang W; An G; Zou D; Wang J; Qiu L; Yi S
Front Immunol; 2023; 14():1184395. PubMed ID: 37483630
[TBL] [Abstract][Full Text] [Related]
2. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.
Mato AR; Roeker LE; Jacobs R; Hill BT; Lamanna N; Brander D; Shadman M; Ujjani CS; Yazdy MS; Perini GF; Pinilla-Ibarz JA; Barrientos J; Skarbnik AP; Torka P; Pu JJ; Pagel JM; Gohil S; Fakhri B; Choi M; Coombs CC; Rhodes J; Barr PM; Portell CA; Parry H; Garcia CA; Whitaker KJ; Winter AM; Sitlinger A; Khajavian S; Grajales-Cruz AF; Isaac KM; Shah P; Akhtar OS; Pocock R; Lam K; Voorhees TJ; Schuster SJ; Rodgers TD; Fox CP; Martinez-Calle N; Munir T; Bhavsar EB; Bailey N; Lee JC; Weissbrot HB; Nabhan C; Goodfriend JM; King AC; Zelenetz AD; Dorsey C; Bigelow K; Cheson BD; Allan JN; Eyre TA
Clin Cancer Res; 2020 Jul; 26(14):3589-3596. PubMed ID: 32198151
[TBL] [Abstract][Full Text] [Related]
4. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA
Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251
[TBL] [Abstract][Full Text] [Related]
5. Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
Shadman M; Manzoor BS; Sail K; Tuncer HH; Allan JN; Ujjani C; Emechebe N; Kamalakar R; Coombs CC; Leslie L; Barr PM; Brown JR; Eyre TA; Rampotas A; Schuh A; Lamanna N; Skarbnik A; Roeker LE; Bannerji R; Eichhorst B; Fleury I; Davids MS; Alhasani H; Jiang D; Hill BT; Schuster SJ; Brander DM; Pivneva I; Burne R; Guerin A; Mato AR
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):515-526. PubMed ID: 37076367
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Mato AR; Ghosh N; Schuster SJ; Lamanna N; Pagel JM; Flinn IW; Barrientos JC; Rai KR; Reeves JA; Cheson BD; Barr PM; Kambhampati S; Lansigan F; Pu JJ; Skarbnik AP; Roeker L; Fonseca GA; Sitlinger A; Hamadeh IS; Dorsey C; LaRatta N; Weissbrot H; Luning Prak ET; Tsao P; Paskalis D; Sportelli P; Miskin HP; Weiss MS; Svoboda J; Brander DM
Blood; 2021 May; 137(20):2817-2826. PubMed ID: 33259589
[TBL] [Abstract][Full Text] [Related]
7. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis.
Nguyen TT; Nhu NT; Tran VK; Viet-Nhi NK; Ho XD; Jhan MK; Chen YP; Lin CF
Sci Rep; 2023 Jun; 13(1):9775. PubMed ID: 37328530
[TBL] [Abstract][Full Text] [Related]
9. Bruton tyrosine kinase inhibitors: can they be optimized for the treatment of neuroinflammatory disorders?
Visentin A; Puthenparampil M; Briani C
Expert Opin Investig Drugs; 2023; 32(12):1105-1111. PubMed ID: 38153100
[TBL] [Abstract][Full Text] [Related]
10. Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study.
Hess G; Dreyling M; Oberic L; Gine E; Zinzani PL; Linton K; Vilmar A; Jerkeman M; Chen JMH; Ohler A; Stilgenbauer S; Thieblemont C; Lambert J; Zilioli VR; Sancho JM; Jiménez-Ubieto A; Fischer L; Eyre TA; Keeping S; Park JE; Wu JJ; Siddiqi R; Reitan J; Wade S; Salles G
Br J Haematol; 2023 Aug; 202(4):749-759. PubMed ID: 36257914
[TBL] [Abstract][Full Text] [Related]
11. Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
Smith CIE; Burger JA
Front Immunol; 2021; 12():689472. PubMed ID: 34177947
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.
Eyre TA; Kirkwood AA; Gohill S; Follows G; Walewska R; Walter H; Cross M; Forconi F; Shah N; Chasty R; Hart A; Broom A; Marr H; Patten PEM; Dann A; Arumainathan A; Munir T; Shankara P; Bloor A; Johnston R; Orchard K; Schuh AH; Fox CP;
Br J Haematol; 2019 May; 185(4):656-669. PubMed ID: 30768675
[TBL] [Abstract][Full Text] [Related]
13. Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders.
Thompson PA; Tam CS
Blood; 2023 Jun; 141(26):3137-3142. PubMed ID: 37156004
[TBL] [Abstract][Full Text] [Related]
14. Approaches for relapsed CLL after chemotherapy-free frontline regimens.
Roeker LE; Mato AR
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):10-17. PubMed ID: 33275712
[TBL] [Abstract][Full Text] [Related]
15. Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.
Fakhri B; Emechebe N; Manzoor BS; Jawaid D; Alhasani H; Edwards M; Tuncer HH
JCO Oncol Pract; 2024 Apr; ():OP2300630. PubMed ID: 38626366
[TBL] [Abstract][Full Text] [Related]
16. A prediction model for severe hematological toxicity of BTK inhibitors.
Jiang D; Song Z; Liu P; Wang Z; Zhao R
Ann Hematol; 2023 Oct; 102(10):2765-2777. PubMed ID: 37491631
[TBL] [Abstract][Full Text] [Related]
17. Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.
Stephens DM; Byrd JC
Blood; 2021 Sep; 138(13):1099-1109. PubMed ID: 34320163
[TBL] [Abstract][Full Text] [Related]
18. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Bruton tyrosine kinase inhibitors monotherapy and combination therapy in lymphocytic leukemia.
Liu X; Hu B; Peng N; Chen L; Hu D; Zhang J; Wang L; Xie Z; Niu S; Lu Q; Lu J; Fang Y
Clin Exp Med; 2023 Dec; 23(8):4237-4248. PubMed ID: 37831432
[TBL] [Abstract][Full Text] [Related]
20. The impact of Bruton's tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia.
Yang S; Wei R; Shi H; Wang Y; Lai Y; Zhao X; Lu J; Schmitz N
Front Oncol; 2024; 14():1396913. PubMed ID: 38835372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
